Psoriatic arthritis trials in Poland

In Poland 13 Also abroad 116

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Bydgoszcz, Cracow, Lublin, Torun, Warsaw
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Where
Bialystok, Bydgoszcz, Elblag, Pruszków, Warsaw
Age
18 years and over
People
300 worldwide
Run by
AbbVie
See details and how to joinNCT06865105
Phase 1Taking people
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Where
Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól, Olsztyn, Płońsk, Poznan, Torun, Warsaw, Wroclaw
Age
18 years and over
People
392 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07290036
Phase 3Taking people
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Where
Krakow, Lodz, Warsaw
Age
1 year to 18 years
People
190 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT03773965
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Rzeszów, Sosnowiec, Warsaw
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 3Taking people
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Where
Cracow, Sosnowiec
Age
2 years to 18 years
People
40 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06668181 · EU 2023-508845-41-00
Phase 3Taking people
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Where
Cracow, Lodz, Warsaw
Age
5 years to 17 years
People
60 worldwide
Run by
Amgen
See details and how to joinNCT04804553 · EU 2023-503435-17-00
Phase 3Taking people
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Where
Bialystok, Białystok, Bytom, Cracow, Dąbrówka, Elblag, Katowice, Lodz, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw
Age
18 years and over
People
1,088 worldwide
Run by
Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00
Phase 3Taking people
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Where
Białystok, Bydgoszcz, Bytom, Cracow, Częstochowa, Dąbrówka, Elblag, Gdynia, Katowice, Lodz, Lublin, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw, Wrocław
Age
18 years and over
People
1,182 worldwide
Run by
Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Where
Cracow, Lodz, Lublin, Sosnowiec, Warsaw
Age
5 years to 17 years
People
40 worldwide
Run by
AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00
Phase 4Taking people
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Where
Bydgoszcz, Bytom, Elblag, Krakow, Kraków, Lublin, Poznan, Warsaw, Warszawa, Wroclaw
Age
18 years and over
People
100 worldwide
Run by
CARE ARTHRITIS LTD.
See details and how to joinNCT06454188 · EU 2023-510242-24-00
Phase 3Not yet taking people in Poland
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
Where
Bialystok, Bydgoszcz, Bytom, Cracow, Częstochowa, Dąbrówka, Debica, Elblag, Gdynia, Katowice, Lodz, Lublin, Nadarzyn, Nowa Sol, Olsztyn, Poznan, Siedlce, Sochaczew, Swidnica, Torun, Warsaw, Warszawa, Wołomin, Wroclaw, Zamość
Age
18 years and over
People
948 worldwide
Run by
MoonLake Immunotherapeutics AG
See details and how to join2025-522471-28-00 · EU 2025-522471-28-00
No phaseTaking people
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Where
Poznan, Wroclaw
Age
18 years to 75 years
People
1,200 worldwide
Run by
AbbVie
See details and how to joinNCT06764693